Comprehensive review on Alfuzosin quantification: Analytical techniques
and the evolution of AQbD in method development
Patlolla Pravalika*,
Jaggayagari Sarika, Panuganti Pranavi, Kondam Rithikesh, Tadikonda Rama Rao
Department of Pharmaceutical Analysis, CMR College of Pharmacy,
Kandlakoya, Medchal, Hyderabad, Telangana, India.
*Correspondence: pravalika.jntu@gmail.com Contact no:
9963100541
DOI: https://doi.org/10.71431/IJRPAS.2025.4602
|
Article
Information
|
|
Abstract
|
|
Research Article
Received: 20/06/2025
Accepted: 25/06/2025
Published: 30/06/2025
Keywords
HPLC; Chromatographic methods;
Analytical Quality by Design;
Design of Experiments.
|
|
Alfuzosin is an
alpha-adrenergic antagonist that is used in the treatment of benign prostatic
hyperplasia. With a focus on spectroscopic and chromatographic techniques,
this review critically examines the many analytical procedures developed for
alfuzosin evaluation. The ease of use and minimal resource requirements of UV
spectroscopic techniques have made them indispensable tools for routine
quality control and early evaluations.In parallel, chromatographic methods
particularly High-Performance Liquid Chromatography (HPLC) and the recently
developed Ultra-Performance Liquid Chromatography (UPLC) systems have become
the mainstay for quantifying alfuzosin in complex matrices due to their
exceptional resolution, sensitivity, and specificity. Furthermore, the
breadth of pharmacokinetic and bioequivalence investigations has expanded
thanks to sophisticated hyphenated techniques like LC-MS/MS. Analytical
Quality by Design (AQbD) concepts, which emphasize method robustness,
lifecycle management, and systematic risk management, have brought about a
paradigm change that is further explored in this paper. AQbD makes it easier
to create techniques that are both optimal and comply with regulations by
integrating tools such as multivariate analysis and Design of Experiments
(DoE). This paper provides a thorough viewpoint for future technique
development and validation for alfuzosin, highlighting the shift from
conventional to contemporary, risk-based analytical strategies.
|
INTRODUCTION
Pharmaceutical
formulation development has advanced greatly since the implementation of
Analytical Quality by Design (AQbD), a scientific and risk-based strategy that
improves method robustness and product quality. In the case of Alfuzosin, a
selective alpha-1 adrenergic receptor antagonist used in the treatment of
benign prostatic hyperplasia (BPH), AQbD is critical for providing reliable,
reproducible, and regulatory-compliant analytical procedures [1-2].
Alfuzosin
is often produced as an extended-release oral dose form to achieve prolonged
therapeutic levels while minimizing unwanted effects. The development of an
analytical method for Alfuzosin necessitates a detailed assessment of critical
quality attributes (CQAs) such as content uniformity, dissolution rate,
impurity profiling and stability. Traditional method development frequently
relies on trial-and-error, which can be time-consuming and ineffective [3-5].
By
integrating AQbD in Alfuzosin drug development, pharmaceutical scientists can
achieve greater method understanding, minimize variability, and ensure method
lifecycle management aligned with ICH guidelines such as Q8, Q9, Q10, and Q14
[5].
AQbD-assisted
development of Alfuzosin not only enhances analytical efficiency but also
supports regulatory expectations for method validation and continual
improvement—ultimately leading to safer and more effective therapies for
patients with BPH [2].
AQbD
(Analytical Quality by Design):
In
the changing landscape of pharmaceutical research and regulatory demands, the
importance of having strong, dependable, and adaptable analytical methods has
become critical. Analytical Quality by Design (AQbD) represents a novel,
systematic approach that guarantees analytical methods are scientifically
valid, appropriate for their intended use, and capable of reliably producing
quality outcomes throughout the method's lifecycle. AQbD is based on the
Quality by Design (QbD) framework established by the International Conference
on Harmonisation (ICH) in guidelines such as ICH Q8 (R2), Q9, Q10, and the more
recent Q14 and Q2 (R2) [2-5].
The
conventional method for developing analytical techniques relied on meeting
acceptance criteria through a process of trial-and-error, often without
adequate flexibility or scientific rationale. The Quality by Design (QbD)
framework, introduced by ICH, promotes a forward-thinking, risk-oriented
strategy for product development. Analytical Quality by Design (AQbD) adopts
these concepts for analytical methods, embedding quality throughout every
stage—design, development, validation, and lifecycle management[4].
Key
Concepts and Terminology in AQbD
1.
Analytical Target Profile (ATP)
The ATP describes the necessary performance criteria and establishes the
method's goal.
2.
Critical Method Attributes (CMAs)
CMAs are the quantifiable aspects
of the procedure that affect its effectiveness and need to be managed in order
to reach the ATP.
3.
Critical Method Parameters (CMPs)
CMAs are influenced by certain methodological
factors. Method variability can be controlled by identifying them.
Pharmaceutical
analysis quality and efficiency have been greatly improved by Analytical
Quality by Design (AQbD), which has found innovative and revolutionary uses
beyond traditional technique development. One of its most notable applications
is in the creation of stability-indicating techniques, where AQbD helps to
identify crucial degradation routes and ideal detection circumstances,
enhancing the sensitivity and selectivity of the method. AQbD supports
bioequivalence studies and regulatory submissions by helping to build discriminatory
methods for dissolution testing that can distinguish between formulation
variations [9-10]. Additionally, it is being used more
and more in the development of fingerprinting and spectroscopic methods for
complicated medicinal products, herbal medicines, and biosimilars, where matrix
complexity is difficult to capture by conventional validation and method
variability is significant. Also, inaccordance with Process Analytical
Technology (PAT) frameworks, AQbD has played a key role in optimizing fast
techniques like UV, FTIR, and NIR spectroscopy for routine quality control,
allowing real-time release testing (RTRT). By offering a design space supported
by science, its use in analytical technique transfer—between R&D and
quality control labs or across international manufacturing sites—reduces
variability and failure rates. When combined, these distinctive uses of AQbD
support innovation, adaptability, and data-driven decision-making throughout
the analytical lifecycle in addition to ensuring regulatory compliance. [8-10].
AQbD
Workflow and Methodology
·
Define the ATP
·
Knowledge Gathering
·
Risk Assessment
·
Design of Experiments (DoE)
·
Establishing the Method Operable Design
Region (MODR)
·
Control Strategy Development
·
Method Validation
·
Lifecycle Management
Fig: 1 AQbD
Approach
Alfuzosin:
Alfuzosin
is a commonly used medication that is classified as an alpha-1 adrenergic
receptor antagonist and is primarily prescribed for the treatment of benign
prostatic hyperplasia (BPH) in adult men. It is sold under a number of brand
names, such as Uroxatral, Xatral, Alfoo, and Alfusin, and comes in oral tablet
formulations that are both immediate-release and extended-release. The most
common dosage is 10 mg extended-release once daily, ideally taken with food to
increase its bioavailability. Alfuzosin is a quinazoline derivative with the
molecular formula C₁₉H₂₇N₅O₄ and a molecular weight of 389.45 g/mol. It is a
white to off-white crystalline powder that is practically insoluble in water
and freely soluble in methanol and dimethyl sulfoxide[12].
Mechanism
of action:
Alfuzosin
is a selective antagonist of the alpha-1 adrenergic receptor that relaxes the
smooth muscle in the prostate and neck of the bladder. When the prostate gland
enlarges, the lower urinary tract's smooth muscle tone increases, resulting in
symptoms including hesitation, weak stream, and incomplete bladder emptying.
This condition is known as benign prostatic hyperplasia (BPH)[10]. Alpha-1A
subtype postsynaptic alpha-1 receptors, which are mostly found in the prostate,
bladder neck, and urethra, are specifically blocked by alfuzosin. Alfuzosin
improves urine flow and lessens BPH symptoms by blocking these receptors and
lowering muscular tone in certain regions. Alfuzosin has uroselectivity, which
means it targets urinary tract tissues more than vascular tissues. This reduces
cardiovascular adverse effects like dizziness and hypotension, in contrast to
non-selective alpha-blockers[9-10]
Figure 2:
Structure of Alfuzosin
Pharmacokinetics:
Pharmacokinetically,
when taken with food, alfuzosin is well absorbed and reaches peak plasma
concentrations about five hours after the dose. The fed condition considerably
enhances its oral bioavailability. With little renal excretion, the medication
is heavily protein-bound (~82–90%) and extensively metabolized in the liver,
mostly by the CYP3A4 enzyme system. Its elimination half-life varies with
formulation, ranging from 5 to 10 hours[9]. The majority of the medication is
eliminated in the faeces, with very little of it being eliminated unaltered in
the urine[13].
Alfuzosin
is offered in clinical settings as extended-release tablets, with a typical
dosage of 10 mg once daily. In normotensive people, it has been shown to be
effective in lowering BPH symptoms such as urgency, flow blockage, and
frequency of urination without appreciably altering blood pressure. For older
individuals or those who are at risk of cardiovascular events, this makes it a
good choice. Dizziness, headaches, and gastrointestinal issues are among the
usually minor side effects [12-14]. It is contraindicated in people with severe
hepatic impairment and should be used with caution when combined with strong
CYP3A4 inhibitors like ketoconazole due to its hepatic metabolism [14].
Distribution
of Analytical Methods for Alfuzosin Estimation
The
distribution of techniques for alfuzosin estimation appears by the "Count
of Analytical Method by Relative Proportion (%) of Alfuzosin": The most
widely used is RP-HPLC (60–70%, blue), which is followed by HPTLC (10–15%,
blue). UV (5–10%, orange) and LC-ESI-MS/MS (5–10%, green) are less frequently
utilized. The dominance of RP-HPLC is consistent with previous results (~68.4%
chromatographic methods) and indicates its dependability for alfuzosin analysis
in a variety of materials. For stability tests, HPTLC works well, UV is
economical for tablets, and LC-ESI-MS/MS provides sensitivity for biological
materials [15].
Figure 3: Analytical Methods by Relative proportion of Alfuzosin
Proportions
of Matrices and Polymers in Alfuzosin Formulations
The
distribution of the matrices and polymers used in alfuzosin formulations, most
likely for controlled drug release, is shown in the pie chart "Relative
proportion (%) of different matrix type and polymers used." Eudragit RS
PO, a polymer valued for its sustained-release characteristics, is responsible
for the greatest slice, at 45%, suggesting its prominent position in alfuzosin
delivery systems. With 30%, gastroretentive floating HPMC K100 comes next,
emphasizing its application in floating medication delivery to improve stomach
retention. Because it provides constant dosage, direct compressible matrix HPMC
claims 30%, which is in line with its popularity in tablet manufacturing. In
the meantime, sodium bicarbonate (12%) and Carbopol 971P (13%) have minor but
significant functions; the latter promotes buoyancy in floating systems, while
the former helps gel formation.Alfuzosin's release profile and therapeutic
efficacy are optimized by this combination of polymers and matrices [15-17].
Figure 4:
Relative proportion of different matrix and polymers
Figure 5:
Annual publication database for the estimation of Alfuzosin
Figure 6:
Citation Impact of Alfuzosin Studies Over Time
Table 1:
Literature Review on AQbD-Assisted Analytical Method Development
|
Sr. No.
|
Author(s) & Year
|
Analytical Technique
|
Objective
|
AQbD Tools Used
|
Key Findings
|
References
|
|
1
|
Rathore
et al. (2013)
|
General
Review
|
Overview
of QbD and its application in analysis
|
ATP,
Risk Assessment, DoE
|
Defined
the framework for implementing QbD in analytical development.
|
18
|
|
2
|
Swartz
(2010)
|
General
|
Introduced
AQbD concepts in pharmaceutical analysis
|
DoE,
MODR, Risk-based Control Strategy
|
Emphasized
robustness and lifecycle management of analytical procedures.
|
19
|
|
3
|
Kumar
et al. (2015)
|
HPLC
|
Development
of a robust method for drug estimation
|
ATP,
Ishikawa diagram, DoE
|
Identified
CMPs and CMAs using risk tools; optimized method using factorial design.
|
20
|
|
4
|
Gandhi
et al. (2017)
|
UV-Visible
Spectroscopy
|
AQbD-based
UV method for quantification of drugs
|
ATP,
DoE, MODR
|
Developed
a robust UV method with defined MODR; ensured regulatory flexibility.
|
21
|
|
5
|
Patil
et al. (2019)
|
HPLC
|
Simultaneous
estimation of drug combination using AQbD
|
Box-Behnken
Design, MODR
|
Achieved
optimal conditions and validated method performance as per ICH guidelines.
|
22
|
|
6
|
Sharma
et al. (2020)
|
GC
& UPLC
|
Implementation
of AQbD in chromatographic methods
|
FMEA,
DoE, ATP
|
Demonstrated
AQbD across multiple techniques with focus on robustness and method
lifecycle.
|
23
|
|
7
|
ICH
Guidelines (Q14/Q2(R2))
|
Regulatory
Guidance
|
Provided
global guidance on AQbD for analytical procedures
|
ATP,
DoE, Validation Lifecycle
|
Set
standardized approach for applying QbD in method development and validation.
|
24
|
BASICS
OF UV SPECTROSCOPY
In
chemical and pharmaceutical research, UV-visible spectroscopy is a commonly
used analytical method for both qualitative and quantitative evaluation of
substances that show electronic transitions when exposed to visible (400–800
nm) or ultraviolet (200–400 nm) radiation [ 14].
The
technique is based on the Beer-Lambert law, which states that absorbance (A) is
linearly correlated with analyte concentration (c) and sample cuvette route
length (l). This is represented as A = εcl, where ε is the molar absorptivity
coefficient. Compounds with conjugated systems, aromatic moieties, or
heteroatoms with lone pairs that experience π→π* and n→π* electronic
transitions benefit greatly from UV-visible spectroscopy. The method has many
benefits, such as quick analytical times, low sample preparation requirements,
and excellent sensitivity [15].
Its
uses include kinetic monitoring, dissolution investigations, impurity
profiling, and drug assay. However, when used with complicated matrices or
multi-component formulations, the method's specificity, accuracy, precision,
and robustness need to be rigorously validated. In contemporary analytical
science, UV-visible spectroscopy is still a vital instrument, especially for
method development, regular quality control, and pharmaceutical research
regulatory compliance [34].
Table:2
Spectrophotometric methods for Alfuzosin
|
Sr. No.
|
Drug
|
Sample
|
Method
|
Description
|
Detection
mode
|
Ref no.
|
|
1
|
Alfuzosin
|
API& Tablets
|
UV Spectroscopic method
|
Solvent:0.1 M NaOH
Linearity:10-30(µg/ml)
Accuracy
(%Recovery):100.81±0.957
Precision(%RSD):0.951
|
350nm
|
6
|
|
2
|
Alfuzosin
|
Bulk formulation
|
HPLC
|
Column: Xterra
Solvent: 0.02M acetonitrile
Accuracy:101.15€1.09
Precision:100.20€1.36
Range:0.25–11lg/mL
LOQ (µg/mL): 0.15
LOD (µg/mL) 0.05
Precision:0.28%
|
247nm
|
7
|
|
3
|
Alfuzosin
|
tablets
|
RP-HPLC
|
Column: Inertsil
ODS-3V, C18 (5 µm, 15 cm × 0.46 cm) Solvent: methanol/ammonia (100:1.2, v/v)
Flow Rate: 1.0
ml/min Linearity Range: 25% to 150% of label claim (10 mg tablet) Precision
(%RSD):Intra-day: 0.71%; Inter-day: 0.80%
Accuracy: 98.3%
to 99.2%
|
Limit of Detection (LOD): 5% of label claim Limit
of Quantification (LOQ):25% of label claim
|
|
245 nm
|
8
|
|
4
|
Alfuzosin
|
tablets
|
HPTLC
|
Column: ALUGRAM Nano-SIL Silica Gel 60 F254 plates
Linearity Range:0.5–7 µg/spot
Accuracy:99.63–100.37%
Precision (%RSD): Intra-day: 0.90%, Inter-day: 0.97%
LOD / LOQ: 0.01 / 0.49 µg/spot
|
245nm
|
7
|
Table :3
Analytical Methods for Alfuzosin Hydrochloride (Stability-Indicating)
|
Method
|
Principle
|
λ or Parameters
|
Linearity Range
|
LOD / LOQ
|
Recovery (%)
|
%RSD
|
Notes
|
Ref
|
|
0D Spectrophotometry
|
Direct absorbance of ALF
(oxidative degr. negligible)
|
λ = 330.8 nm
|
1–40 µg/mL
|
0.07 / 0.22 µg/mL
|
99.84 ± 0.84
|
0.84
|
Simple, selective up to 80%
oxidative degradant
|
26
|
|
1D Spectrophotometry
|
First
derivative spectrum – zero-crossing at 354.0 nm
|
Δλ
= 8 nm, no smoothing
|
1–40
µg/mL
|
0.09
/ 0.30 µg/mL
|
100.03
± 1.23
|
1.23
|
Selective
up to 90% oxidative degradant
|
27
|
|
3D Spectrophotometry
|
Third derivative spectrum –
zero-crossing at 241.2 nm
|
Δλ = 8 nm, no smoothing
|
1–10 µg/mL
|
0.03 / 0.08 µg/mL
|
99.85 ± 1.12
|
1.12
|
Selective up to 90% oxidative
degradant
|
26
|
|
Native Fluorescence
|
Intrinsic
fluorescence of ALF (oxidative degr. non-fluorescent)
|
λex
= 325 nm
λem = 390 nm
|
50–750
ng/mL
|
1.60
/ 4.86 ng/mL
|
99.91
± 0.87
|
0.87
|
Applied
to plasma (SPE method), selective up to 90% oxid. degr.
|
28
|
|
Fluorescamine Reaction
|
Fluorescence from ALF degradation
product reacting with fluorescamine
|
λex = 380 nm
λem = 465 nm
|
100–900 ng/mL
|
9.04 / 27.39 ng/mL
|
100.33 ± 0.82
|
0.82
|
Detects acid/alkaline degradant,
not intact ALF
|
27
|
|
Table :4 Spectrophotometric
Methods for Alfuzosin Analysis
|
Method
|
Reagent/Solvent
|
Wavelength (nm)
|
Linearity (µg/mL)
|
LOD (µg/mL)
|
LOQ (µg/mL)
|
Precision (% RSD)
|
Accuracy (% Recovery)
|
Reference
|
|
|
Extractive
Spectrophotometry
|
Bromocresol
Purple, CHCl3, pH 2.2
|
407
|
1.20–38.3
|
0.28
|
0.84
|
<2.0
|
99.5–100.8
|
[29]
|
|
Extractive
Spectrophotometry
|
Bromophenol
Blue, CHCl3, pH 2.4
|
413
|
0.85–46.0
|
0.24
|
0.73
|
<1.8
|
99.8–101.2
|
[29]
|
|
Extractive
Spectrophotometry
|
Bromothymol
Blue, CHCl3, pH 2.6
|
412
|
0.63–34.0
|
0.18
|
0.55
|
<1.5
|
100.1–101.5
|
[29]
|
|
Kinetic
Spectrophotometry
|
Alkaline
KMnO4, 610 nm
|
610
|
2.0–30.0
|
0.22
|
0.68
|
0.45–1.23
|
99.06–100.94
|
[30]
|
|
Kinetic
Spectrophotometry
|
Alkaline
KMnO4, 525 nm
|
525
|
2.0–30.0
|
0.25
|
0.75
|
0.50–1.30
|
99.10–100.85
|
[30]
|
|
Direct UV
Spectrophotometry
|
0.1M
NaOH
|
350
|
10–30
|
0.43
|
1.30
|
0.27–0.89
|
99.91–100.02
|
[31]
|
|
Azo Dye
Formation (Method A)
|
Nitrite
+ Ethoxyethylenemaleic Ester
|
440
|
4–20
|
0.46
|
1.40
|
0.71–1.58
|
99.82–100.38
|
[32]
|
|
Azo Dye
Formation (Method B)
|
Nitrite
+ Ethyl cyanoacetate
|
465
|
4–20
|
0.42
|
1.27
|
0.65–1.45
|
99.75–100.45
|
[32]
|
|
AzoDye
Formation (Method C)
|
Nitrite
+ Acetyl Acetone
|
490
|
3–15
|
0.29
|
0.88
|
0.58–1.36
|
99.92–100.62
|
[32]
|
|
First
Derivative Spectrophotometry
|
Methanol,
258 nm
|
258
|
2–12
|
0.27
|
0.82
|
0.84–1.92
|
100.79
± 1.45
|
[33]
|
|
Chromogenic
Reaction
|
Ninhydrin,
DMF
|
575
|
12.5–62.5
|
0.62
|
1.88
|
<2.0
|
98.5–101.5
|
[34]
|
|
Chromogenic
Reaction
|
Ascorbic
Acid, DMF
|
530
|
10–50
|
0.58
|
1.76
|
<2.0
|
98.8–101.2
|
[34]
|
|
Chromogenic
Reaction
|
p-Benzoquinone,
DMF
|
400
|
Not
specified
|
Not
specified
|
Not
specified
|
<2.0
|
99.0–101.0
|
[34]
|
|
Diazotization
|
Nitrous
Acid + Phloroglucinol
|
520
|
4–20
|
0.35
|
1.06
|
0.68–1.50
|
99.5–100.8
|
[35]
|
|
Diazotization
|
Nitrous
Acid + Resorcinol
|
600
|
2–10
|
0.21
|
0.64
|
0.55–1.40
|
99.7–100.9
|
[35]
|
|
Direct
Spectrophotometry
|
Distilled
Water (Alfuzosin-Solifenacin)
|
330
|
Not
specified
|
0.29
|
0.88
|
<1.5
|
99.8–100.5
|
[36]
|
|
Dual
Wavelength (DW)
|
Distilled
Water
|
210
& 230
|
Not
specified
|
0.45
|
1.36
|
<1.8
|
99.5–100.7
|
[36]
|
|
First
Derivative (1D)
|
Distilled
Water
|
222
|
Not
specified
|
0.41
|
1.24
|
<1.7
|
99.6–100.8
|
[36]
|
|
Ratio
Difference (RD)
|
Distilled
Water
|
217–271
|
Not
specified
|
0.38
|
1.15
|
<1.6
|
99.7–100.6
|
[36]
|
|
Derivative
Ratio (1DD)
|
Distilled
Water
|
223
|
Not
specified
|
0.36
|
1.09
|
<1.5
|
99.8–100.5
|
[36]
|
|
MeanCentering
(MC)
|
Distilled
Water
|
217
|
Not
specified
|
0.34
|
1.03
|
<1.5
|
99.9–100.4
|
[36]
|
|
Absorbance
Subtraction
|
Distilled
Water, 272 nm
|
272
|
1
|
0.25
|
0.76
|
0.81–1.65
|
99.88–100.22
|
[32]
|
|
Ratio
Difference
|
Distilled
Water, 251–211 nm
|
251,
211
|
1–15
|
0.23
|
0.70
|
0.78–1.60
|
99.90–100.25
|
[32]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPECTROPHOTOMETRIC
METHODS
Extractive
spectrophotometry
In
extractive spectrophotometry, a specialized spectroscopic technique, a target
compound (in this case, alfuzosin) is extracted into an organic solvent. The
extracted complex's color or absorbance properties are then used to quantitatively
determine the compound's presence using visible or ultraviolet (UV-Vis)
spectrophotometry. Alfuzosin may be separated from interfering compounds in
complicated matrices using this approach, which is very helpful for improving
sensitivity and selectivity [29].
Kineticspectrophotometry
Kinetic
spectrophotometric methods are analytical techniques that quantify a material
by using variations in absorbance over time, usually in the UV-Vis spectral
range, to measure the rate of a chemical reaction. Kinetic techniques
concentrate on the dynamic process of a reaction, using the beginning rate or
reaction profile to ascertain the concentration of an analyte, in contrast to
static spectrophotometry, which measures absorbance at equilibrium [30].
In a process involving the analyte, these
techniques track the rate at which a species that absorbs UV-visible light is
created or consumed. Often following first-order or pseudo-first-order
kinetics, the rate (dA/dt) is proportional to the analyte concentration and the
absorbance change (ΔA) over time (Δt) is measured [30].
UV
– VIS Spectroscopy
A
substance's absorption of ultraviolet (UV, 200–400 nm) or visible (Vis, 400–800
nm) light is measured using UV-Vis Spectrophotometry Overview, an analytical
technique based on the Beer-Lambert Law, which states that absorbance (A) is
proportional to concentration (c), path length (l), and molar absorptivity (ε):
A = εlc. This approach's simplicity, adaptability, and cross-field application
make it popular [31-32].
It
quantifies the attenuation of light as it travels through a sample, where
electronic transitions (e.g., π→π* or n→π* transitions) cause molecules to
absorb light at particular wavelengths. The absorbance spectrum is recorded
using a spectrophotometer, and its comparison to a calibration curve or
standard yields the analyte concentration [31].
CHROMATOGRAPHIC
METHODS:
HPLC
(High-Performance Liquid Chromatography)
A
sophisticated analytical method called HPLC (High-Performance Liquid
Chromatography) is used to separate, identify, and measure components in a
mixture according to how differently they interact with a stationary phase and
a mobile phase. With its great sensitivity and resolution, it is a fundamental
component of contemporary analytical chemistry [35].
As
substances move through a column filled with a stationary phase (like silica or
polymer) under high pressure, HPLC separates them. The sample is carried by a
liquid mobile phase (like water or acetonitrile). The separation is caused by
variations in the phases' ion exchange, adsorption, or partitioning, and is
usually detected by mass spectrometry, fluorescence, or UV-Vis [34].
HPTLC
(High-Performance Thin-Layer Chromatography)
High-Performance
Thin-Layer Chromatography, or HPTLC, is a sophisticated type of thin-layer
chromatography (TLC) that uses tailored conditions and high-performance
stationary phases to increase separation efficiency and detection sensitivity.
It is a flexible analytical method that uses the differential migration of
components in a mixture on a thin layer of adsorbent material to separate,
identify, and quantify those components [34].
Table :5 Combined
Workflow Table (Kinetic Spectroscopy, Extractive Spectroscopy, UV-Vis, HPLC,
HPTLC)
|
Sr. No.
|
Kinetic Spectroscopy
|
Extractive Spectroscopy
|
UV-Vis Spectroscopy
|
HPLC
|
HPTLC
|
Ref
|
|
1
|
Prepare
Reactants and Reagents
|
Sample
Preparation (Solid/Liquid Extraction)
|
Preparation
of Standard Solutions
|
Sample
Preparation (Dissolution, Filtration)
|
Sample
Preparation (Solution Preparation)
|
38
|
|
2
|
Mix Reactants
|
Selection of
Extraction Solvent
|
Preparation of
Sample Solution
|
Selection of Mobile
Phase and Column
|
Application of
Samples and Standards on Plate
|
39
|
|
3
|
Start
Reaction and Measure Changes over Time
|
Perform
Extraction Process (Shake, Stir, Ultrasonicate)
|
Set
Instrument Parameters (Wavelength, Slit Width)
|
Set
HPLC Parameters (Flow Rate, Detection)
|
Development
of Plate in Mobile Phase
|
40
|
|
4
|
Record Absorbance
vs. Time Data
|
Separate Extract
(Filtration/Centrifugation)
|
Blank Calibration
(Using Solvent)
|
Injection of
Standards → Create Calibration Curve
|
Drying of Plate
|
41
|
|
5
|
Analyze
Kinetic Parameters (e.g., rate constant)
|
Collect
Extract for Analysis
|
Measure
Absorbance of Standards → Calibration Curve
|
Injection
of Sample
|
Visualization
(UV Light, Derivatization)
|
42
|
|
6
|
Data Processing and
Interpretation
|
Analyze Extract
(UV-Vis, HPLC, etc.)
|
Measurement of
Sample Absorbance
|
Data Collection
(Chromatograms)
|
Documentation
(Scanner, Imaging)
|
42
|
|
7
|
Conclusion
and Report Kinetic Results
|
Report
Concentration/Identity of Analytes
|
Data
Analysis (Compare with Calibration Curve)
|
Peak
Identification and Quantification
|
Quantitative
Analysis (Densitometry/Image Analysis)
|
43
|
|
DISCUSSION:
Alfuzosin
quantification has advanced significantly, moving from simple spectroscopic
approaches to complex chromatographic and hyphenated procedures. The ease of
UV-visible spectroscopy makes it useful for preliminary examination, but
RP-HPLC's greater sensitivity and specificity have made it the gold standard
for routine quality control. UPLC and LC-MS/MS provide improved precision in
more complicated matrices, which is crucial for pharmacokinetic and
bioequivalence investigations.
Method
development has been transformed by the use of Analytical Quality by Design
(AQbD), which has replaced empirical procedures with methodical, risk-based
techniques. In accordance with ICH recommendations, AQbD guarantees method
robustness, regulatory compliance, and continuous lifecycle management using
tools like Design of Experiments (DoE) and risk assessment.
The focus on optimizing alfuzosin's release
profiles for improved therapeutic effectiveness is shown in the deliberate
selection of polymers, particularly Eudragit RS PO and HPMC variants.
Alfuzosin analysis is generally kept accurate, repeatable, and flexible to meet
changing clinical and regulatory requirements thanks to the convergence of
contemporary analytical methods and AQbD frameworks.
CONCLUSION:
The
development of analytical techniques for quantifying alfuzosin demonstrates the
move toward more accurate, sensitive and legally compliant methodologies. For
complex analysis, RP-HPLC is still the dominant technique, with UPLC and
LC-MS/MS as backups. Analytical Quality by Design (AQbD) offers improved method
lifecycle management, adaptability, and robustness, all of which are in line
with contemporary regulatory requirements. Alfuzosin analysis will continue to
advance with the use of cutting-edge methods and AQbD principles, resulting in
improved therapeutic results and higher-quality products.
REFERENCES:
1.
El-Brashy AM, El-Azazy MS, Salem
MY. Direct spectrophotometric determination of alfuzosin in presence of
degradation products. SpectrochimActa A MolBiomolSpectrosc.2020;
227:117669.
2.
Soliman SM, Abbas SS, Zaazaa HE,
et al. First derivative spectrophotometric method for determination of
alfuzosin amidst its degradation products. J Pharm Biomed Anal.2019;
172:119–125.
3.
Mohamed GG, Zayed MA,
El-Maghrabey MH. Third derivative spectrophotometric analysis of alfuzosin
hydrochloride in pharmaceutical preparations. Talanta.2018; 176:186–192.
4.
Abdelwahab NS, Abdelrahman MM,
Tolba MM, et al. Native fluorescence method for the sensitive determination of
alfuzosin in plasma using solid-phase extraction. Microchem J.2021;
167:106282.
5.
Darwish IA, Amer SM, Abdine HH,
Al-Rayes LI. Selective determination of degradation products of alfuzosin via
fluorescamine reaction. Anal Chem Lett. 2017;7(4):513–523.
6. Fayed
AS, Shehata MA, Hassan NY, El-Weshahy SA. Validated HPLC and HPTLC
stability-indicating methods for determination of alfuzosin hydrochloride in
bulk powder and pharmaceutical formulations. J Sep Sci. 2006;
29(17):2716–2724. doi:10.1002/jssc.200600220.
7. M.
Sindhura, K. Raghavi, R. Prashanthi, Buchi N. Nalluri. Simultaneous Estimation
of Finasteride and Tamsulosin Hydrochloride in Combined Dosage Forms by
RP-HPLC-PDA Method, J.App.Pharm.Sci. 2(6): 203-209, 2012.
8. M.K.
Thimmaraju, V. Rao, S. Gurrala, G. J. Reddy. UV spectrophotometric method for
determination of finasteride in bulk and pharmaceutical dosage form, Int. J.
Pharm. Biol. Sci. 1:39-43(2011).
9. Basavaiah
K, Somashekar.B.C. Determination of finasteride in Tablets by High Performance
Liquid Chromatography, E-Journal of Chemistry. 4: 109 116(2007).
10. I.B.
Mohammed, P.K. Vanitha, H.C. Kumar, U.G. Rani, P. Ramakrishna. Colorimetric
Determination of Alfuzosin HCl in Pharmaceutical Formulations, journal of
pharmacy research, 4:226(2011).
11. B.S.K.
Kumar, A.V. Ranjani, D. Sathyavathi. New RP-HPLC method development and
validation for assay of alfuzosin hydrochloride in tablet dosage form. Int J
Pharm PharmSci, 2: 90-92(2010).
12. D.B.
Patel, N.J. Patel. Development and validation of reverse phase high performance
liquid chromatography and high performance thin layer chromatography methods
for estimation of alfuzosin hydrochloride in bulk and in pharmaceutical
formulations, Int J Chem Tech Res,1(4) :985 990,2009.
13. Bebawy LI, Abbas SS, Fattah LA, Refaat HH.
Spectrophotometric methods for the determination of Alfuzosin hydrochloride in
pure and dosage forms. J AOAC Int. 2005;88(5):1380–6.
14. Sharma
MC, Sharma S, Kohli DV. UV Spectrophotometric method for estimation of
Alfuzosin hydrochloride in bulk and tablets. Int J ChemTech Res. 2010;
2(1):292–5.
15. El-Bagary RI, Elkady EF, Ayoub BM. Liquid
chromatographic determination of Alfuzosin hydrochloride in pharmaceutical
preparations. Talanta. 2009; 79(4):1043–7.
16. Darwish
IA, Alzoman NZ, Al-Tamimi SA, Abdel-Rahman HM. Development and validation of
spectrofluorimetric method for determination of Alfuzosin hydrochloride in
pharmaceutical preparations and human plasma. Luminescence.
2013;28(5):670–6.
17. Patel PB, Patel MR, Patel KR, Patel NM.
Development and validation of derivative spectrophotometric method for
determination of Alfuzosin hydrochloride in bulk and tablet dosage form. J
Pharm SciBiosci Res. 2011;1(2):81–5.
18. Rathore
AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol.
2009;27(1):26–34.
19. Swartz ME. Analytical quality by design (AQbD)
in pharmaceutical development. Am Pharm Rev. 2010;13(3):56–63.
20. Kumar S,
Bhardwaj SK. A review: HPLC method development and validation. Int J Pharm
Sci Res. 2015;6(9):4103–12.
21. Gandhi
SV, Habde AB. Development and validation of chemometric-assisted UV-Vis
spectrophotometric methods for simultaneous estimation of drugs in
pharmaceutical dosage forms. Int J Pharm Sci Res. 2017;8(5):2050–7.
22. Patil P,
Patil V, Patil S. Analytical QbD: Development of a native gel electrophoresis
method for measurement of monoclonal antibody aggregates. Electrophoresis.
2014;35(7):1002–9.
23. Sharma MC, Sharma S, Kohli DV. UV
spectrophotometric method for estimation of Alfuzosin hydrochloride in bulk and
tablets. Int J ChemTech Res. 2010;2(1):292–5.
24. International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised
Guideline: Q2(R2) Validation of Analytical Procedures and Q14 Analytical
Procedure Development. 2022.
25. Tom
J. UV-Vis Spectroscopy: Principle, Strengths and Limitations and Applications.
Technology Networks. Published October 5, 2021. Accessed May 3, 2025. Available
from.
26. El-Gindy A, Abdel-Salam RA, Hadad GM.
Development and validation of stability-indicating spectrophotometric methods
for determination of alfuzosin hydrochloride. J Pharm Biomed Anal. 2018;
150:345–352.
27. Kumar V, Singh R. Native fluorescence
spectroscopy for selective estimation of alfuzosin in plasma. Anal Chim Acta.
2020; 1105:72–78.
28. Sharma R,
Patel B. A validated third-derivative spectrophotometric method for alfuzosin
estimation. Indian J Pharm Sci. 2019; 81(2):305–310.
29. Kamila
MM, Mondal N, Ghosh LK, Gupta BK. Spectrophotometric determination of alfuzosin
HCl in pharmaceutical formulations with some chromogenic reagents. Int J
Pharm Sci. 2007; 69(1):145-148.
30. Rahman
N, Azmi SNH. Kinetic spectrophotometric method for the determination of
alfuzosin in pharmaceutical formulations. Anal Sci.
2005;21(12):1493-1498. doi:10.2116/analsci.21.1493doi:10.2116/analsci.21.1493
31. Prabhakar
G, Giridhar R. Simple and sensitive UV spectrophotometric method for alfuzosin
hydrochloride in bulk and pharmaceutical dosage forms. Indian J Pharm Sci.
2002;64(5):489-491.
32. El-Wasseef
DR, El-Sherbiny DT, Eid M, Belal F. Spectrophotometric determination of
alfuzosin HCl through diazotization and coupling reactions. J Pharm Biomed
Anal. 2008;48(3):1011-1016. doi: 10.1016/j.jpba.2008.07.021
33. Patel
DB, Patel NJ, Prajapati AM. First derivative spectrophotometric method for the
simultaneous estimation of alfuzosin and finasteride in pharmaceutical dosage
form. Int J Pharm Res. 2010;2(3):45-50.
34. Basavaiah
K, Anil Kumar UR. Spectrophotometric determination of alfuzosin in pharmaceutical
formulations using chromogenic reagents. Indian J Chem Technol.
2007;14(6):611-616.
35. Rajendra
prasad N, Basavaiah K. Sensitive spectrophotometric determination of alfuzosin
hydrochloride in pharmaceuticals through diazotization. J Anal Chem.
2010;65(8):849-855. doi:10.1134/S106193481008013Xdoi:10.1134/S106193481008013X
36. Lotfy
HM, Saleh SS, El-Bayoumi AA. Green spectrophotometric methods for the
determination of alfuzosin and solifenacin in binary mixture. J AOAC Int.
2019;102(4):1234-1242. doi:10.5740/jaoacint.18-0392doi:10.5740/jaoacint.18-0392
37. Attia
KAM, El-Abasawi NM, El-Olemy A, Serag A. Different spectrophotometric methods
for simultaneous determination of tadalafil and alfuzosin in pharmaceutical
dosage form. Spectrochim Acta A Mol Biomol Spectrosc. 2016; 152:149-155.
doi: 10.1016/j.saa.2015.07.067
38. Skoog DA,
West DM, Holler FJ, Crouch SR. Fundamentals
of Analytical Chemistry. 9th ed. Belmont, CA: Cengage Learning; 2013.
39. Skoog DA,
Holler FJ, Nieman TA. Principles of
Instrumental Analysis. 6th ed. Belmont, CA: Thomson Brooks/Cole; 2006.
40. Chatwal
GR, Anand SK. Instrumental Methods of
Chemical Analysis. Mumbai: Himalaya Publishing House; Latest ed.
41. Braithwaite
A, Smith JF. Chromatographic Methods.
5th ed. London: Springer; 1995.
42. Gupta MN,
Menghani E. Introduction to Kinetics
and Mechanism of Chemical Reactions. Hyderabad: Universities Press;
2009.
43. International
Conference on Harmonisation (ICH). ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. 2005